Post

C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy

C4XD is eligible to receive development and commercial milestone payments worth $385.8m from AstraZeneca.

How remote monitoring tech is enhancing healthcare for ageing populations

Free Whitepaper Precision Medicine: Streamlining Treatments and Drug Development Precision medicine has the potential to radically change the way health…

UK Government to fund research into new obesity treatments

This funding could offer patients treatments and digital technologies, which were found to be safe in trials.

Biocytogen and ADC to evaluate antibodies for three cancer targets

According to the agreement, ADC Therapeutics will make an upfront payment to Biocytogen.

Who’s innovating where? Patent activity related to 3D printing decreased by 3% in the pharmaceutical industry in Q3 2022